User login
Key clinical point: Neoadjuvant chemotherapy (NAC) that did vs did not contain cisplatin improved survival in patients with operable triple-negative breast cancer (TNBC), especially those with residual cancer burden (RCB) class II/III, a group that is typically associated with worse prognosis.
Major finding: Patients who did vs did not receive cisplatin-based regimens in the overall population reported significantly improved distant disease-free survival (unadjusted hazard ratio [HR] 0.127; P < .001), especially those in the RCB class II/III group (HR 0.192; P = .013).
Study details: Findings are from a retrospective cohort study including 138 previously untreated patients with stage I-III TNBC who received NAC with (n = 52) or without (n = 86) cisplatin.
Disclosures: This study was supported by a Japan Society for Promotion of Science KAKENHI Grant. Several authors declared receiving grants, consulting fees, or honoraria from, or serving as a members of advisory boards, boards of directors, or as an associate editor for various sources.
Source: Yamaguchi A et al. Comparison of cisplatin-based versus standard preoperative chemotherapy in patients with operable triple-negative breast cancer: Propensity score matching and inverse probability of treatment weighting analysis. Breast Cancer Res Treat. 2023 (Dec 21). doi: 10.1007/s10549-023-07163-z
Key clinical point: Neoadjuvant chemotherapy (NAC) that did vs did not contain cisplatin improved survival in patients with operable triple-negative breast cancer (TNBC), especially those with residual cancer burden (RCB) class II/III, a group that is typically associated with worse prognosis.
Major finding: Patients who did vs did not receive cisplatin-based regimens in the overall population reported significantly improved distant disease-free survival (unadjusted hazard ratio [HR] 0.127; P < .001), especially those in the RCB class II/III group (HR 0.192; P = .013).
Study details: Findings are from a retrospective cohort study including 138 previously untreated patients with stage I-III TNBC who received NAC with (n = 52) or without (n = 86) cisplatin.
Disclosures: This study was supported by a Japan Society for Promotion of Science KAKENHI Grant. Several authors declared receiving grants, consulting fees, or honoraria from, or serving as a members of advisory boards, boards of directors, or as an associate editor for various sources.
Source: Yamaguchi A et al. Comparison of cisplatin-based versus standard preoperative chemotherapy in patients with operable triple-negative breast cancer: Propensity score matching and inverse probability of treatment weighting analysis. Breast Cancer Res Treat. 2023 (Dec 21). doi: 10.1007/s10549-023-07163-z
Key clinical point: Neoadjuvant chemotherapy (NAC) that did vs did not contain cisplatin improved survival in patients with operable triple-negative breast cancer (TNBC), especially those with residual cancer burden (RCB) class II/III, a group that is typically associated with worse prognosis.
Major finding: Patients who did vs did not receive cisplatin-based regimens in the overall population reported significantly improved distant disease-free survival (unadjusted hazard ratio [HR] 0.127; P < .001), especially those in the RCB class II/III group (HR 0.192; P = .013).
Study details: Findings are from a retrospective cohort study including 138 previously untreated patients with stage I-III TNBC who received NAC with (n = 52) or without (n = 86) cisplatin.
Disclosures: This study was supported by a Japan Society for Promotion of Science KAKENHI Grant. Several authors declared receiving grants, consulting fees, or honoraria from, or serving as a members of advisory boards, boards of directors, or as an associate editor for various sources.
Source: Yamaguchi A et al. Comparison of cisplatin-based versus standard preoperative chemotherapy in patients with operable triple-negative breast cancer: Propensity score matching and inverse probability of treatment weighting analysis. Breast Cancer Res Treat. 2023 (Dec 21). doi: 10.1007/s10549-023-07163-z